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study, acidosis induced with acetazolamide treatment resulted in the appearance of B2 in the apical membrane of -intercalated cells, suggesting that another H + -ATPase or an H + -ATPase that includes both B1 and B2 can be recruited to the plasma membrane when assembly of the holoenzyme is stressed. 13 Intercalated cells are highly dynamic and can rapidly respond to the signals induced by systemic acid / base changes to reduce or increase their rate of vectoral acid secretion. Th e major mechanism utilized for adjusting the transport rate in both acute and chronic states is up-or downregulation of the H + -ATPase and anion exchangers (AE1 in -intercalated and pendrin in -intercalated cells) inserted into the apical and basolateral membranes. Long-term adaptation utilizes this same response in addition to changes in the overall expression level of these transporters and, at some yet-to-bequantitated rate, the interconversion of -and -intercalated cells.
see original article on page 1016
In 1961, Sarles et al. fi rst described an entity of sclerosing pancreatitis with hypergammaglobulinemia and hypothesized that this entity was an autoimmune phenomenon. 1 Since then, this disease has been recognized as being related to increased IgG4, both as elevated levels of IgG4 in patient serum and in tissue sections with increased IgG4 + plasma cells. In the past few years, the extrapancreatic features of ' autoimmune pancreatitis ' (AIP) have been recognized, 2 thus calling for a new name for the disease. Now, IgG4-related systemic disease has been described in nearly every organ and organ system, fi rst recognized in the pancreas, and then recognized in the liver, gallbladder, other gastrointestinal sites (sometimes including infl ammatory bowel disease), salivary or lacrimal glands, lung, breast, retroperitoneum, lymph nodes, pituitary gland, prostate, and aorta. Th e entity of IgG4-related systemic disease, while enjoying increased attention in the literature, has been largely unrecognized in regular clinical practice, especially when it aff ects organs outside of the pancreas. This disease is even more likely to be un diagnosed in the kidney, when renal biopsies of IgG4-related disease are diagnosed simply as tubulointerstitial nephritis (TIN) without a more specific diagnosis indicating the underlying cause of this disease pattern. As with glomerular diseases, which are, for the most part, specifi c and well defi ned in terms of histologic, ultrastructural, and immunophenotypic features, pathologists and clinicians should strive to identify and describe tubulointerstitial diseases in the same manner, with clinicopathologic correlation. TIN may be immunologically mediated, associated with drugs (allergic or toxic), associated with infection (either by direct infection or in reaction to a distant infection), hereditary, or metabolic or may be due to other causes ( Figure 1 ). Overlap between categories is sometimes seen. TIN may also be a primary disease or may be associated with systemic disease. Recognition of the specifi c type of TIN then guides appropriate patient therapy.
IgG4-related tubulointerstitial nephritis
Saeki et al. 3 (this issue), in a multicenter study, describe the largest histopathologic series to date of renal parenchymal involvement by IgG4-related disease. From a group of 153 patients with suspected IgG4-related systemic disease, approximately 20 % had evidence of renal parenchymal disease, including radiographic abnormalities, abnormal urinalysis, or renal dysfunction. Th is percentage is similar to that seen in radiographic studies demonstrating 30 % of patients with AIP as having renal parenchymal involvement. 4 Th e predominant feature in 23 patients whose renal tissue was examined was TIN, with characteristic histologic features of a plasma cell-rich infiltrate with a significant number of eosinophils in some cases. IgG4 immunostaining revealed at least a moderate amount of IgG4 + plasma cells in all cases. Furthermore, all of the 22 patients with a measurement had an elevated serum IgG4 level, and the other patient had an elevated serum total IgG level. Nearly all of the patients included in the study had some form of extrarenal involvement by this autoimmune disease, notably 13 of 23 without a diagnosis of (pancreatic) AIP.
Th e study by Saeki et al. 3 draws attention to and further defi nes this specifi c type of TIN. Th e presence of a plasma cellrich TIN in a patient with a renal mass or enlarged kidneys on imaging studies, hypergammaglobulinemia, hypocomplementemia, or a history of an extrarenal inflammatory mass should alert the pathologist to consider this entity, and perhaps to perform IgG4 immunostaining. Although not specifi cally studied by Saeki et al. , tubular basement membrane immune complex deposition is a helpful feature to suggest an autoimmune etiology of TIN and may show IgG4-dominant staining in cases of IgG4-related TIN. 5 How useful is IgG4 immunostaining in cases of TIN? In the pancreas, a moderate to marked increase in IgG4 + plasma cells (usually defi ned as at least 10 cells per high-power fi eld in the most dense areas) is one of the diagnostic criteria for AIP. 6 In one study, although such an increase was diagnostically helpful when present, only 72 % of AIP patients had at least moderately increased IgG4 + plasma cells in pancreatic specimens. 6 Th is fi nding correlates with other studies that show elevated serum IgG4 in only about 70 % of patients. Elevated serum IgG4 levels and tissue IgG4 + plasma cells tend to occur together. 7 Certainly, IgG4 immunostaining is useful in supporting an etiologic link between AIP and its extrapancreatic involvement in the kidney. Th e diagnostic specifi city of IgG4 staining in the kidney is unknown, however, and so the pathologist cannot rely on this one test to make the diagnosis.
Furthermore, in the study by Saeki et al. , 3 patients were selected for inclusion on the basis of having increased IgG4 in tissue or in the serum, and so those potential patients with ' low-IgG4 ' AIPassociated disease were necessarily excluded. Extrapolating from the pancreatic literature, ' low-IgG4 ' TIN associated with a systemic autoimmune disease may aff ect up to 30 % of these TIN cases. Defi nition of ' low-IgG4 ' autoimmune TIN, therefore, remains an open question.
A few scattered case reports exist of glomerular disease in IgG4-related systemic disease, mostly reports of membranous glomerulonephritis (MGN). This largest series of IgG4-related TIN includes two cases of MGN ( ~ 9 % of the cases), along with one case of IgA nephropathy, and three cases of other (undefi ned) glomerular disease. MGN as a potential etiologic link with IgG4-related systemic disease is intriguing because idiopathic MGN is also an IgG4-dominant disease, such that these may have a common pathogenetic link. IgG4 itself is an unusual antibody and has some unusual physical characteristics. It is the rarest IgG subclass in the circulation of normal individuals. Elevated titers of IgG4 are found in conditions of chronic antigen exposure; beekeepers, for example, show elevated IgG4 directed against bee venom, and patients undergoing allergen immunotherapy develop increased IgG4 titers against the allergen. Compared with IgG1, the IgG4 molecule has weaker interchain disulfi de bridges, so that immunoglobulin half-molecules, composed of one heavy chain and one light chain, dissociate from each other. Once these dissociate, an IgG4 half-molecule may reassociate with another halfmolecule with specifi city for a diff erent antigen. 7, 8 When IgG4 encounters antigen, it can only form small, and presumably harmless, immune complexes and may block antigen binding by the more pathogenic IgG1. IgG4 is also unable to fi x complement. In these ways, IgG4 is thought to act as an anti-infl ammatory molecule that can temper the immune response, at least in some circumstances.
While IgG4 is an ' anti-inflammatory ' immunoglobulin, it is perplexing that it is found to be increased in some disease states, most notably IgG4-related systemic disease. Th e mechanism of this disease and its association with IgG4 is unclear. IgG4 class switching depends on interleukin-4 and/or interleukin-13 mainly secreted by T-helper 2 cells. Th ese are the same cytokines that promote an IgE response, although IgG4 antibody may be present in the absence of IgE antibody against a particular antigen. Interleukin-10 (IL-10) has an eff ect on IgG4 versus IgE class switching 9 and may be required for IgG4 class-switched B cells to diff erentiate into IgG4-secreting plasma cells. One may speculate that, in IgG4-related systemic disease, an initial insult and process involving production of antiinfl ammatory cytokines, including IL-10 and tumor necrosis factor-α , along with fi brogenic IL-13, drives increased fi brosis, induction of IgG4 class-switched B cells, and production and massive expansion of IgG4-secreting plasma cells.
TIN is a disease pattern with heterogeneous causes, both immune and nonimmune. Th e clinical presentation, laboratory results, and biopsy features are all considered to make a specifi c diagnosis. Th rough the work of Saeki et al. , 3 we now have a clearer view of the clinicopathologic features of a specifi c type of TIN that is part of systemic IgG4-related disease, which in turn will aid pathologists and clinicians in recognizing and offering appropriate treatment for this disease.
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Within the past few years, it has become apparent that fi broblastic growth factor 23 (FGF23), a bone-derived phosphaturic 
